| 7.22 -0.64 (-8.14%) | 05-29 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 17.65  |
1-year : | 23.73 |
| Resists | First : | 15.11 |
Second : | 20.31 |
| Pivot price | 11.58  |
|||
| Supports | First : | 6.69 |
Second : | 5.56 |
| MAs | MA(5) : | 8.64 |
MA(20) : | 12.76 |
| MA(100) : | 5.98 |
MA(250) : | 3.65 |
|
| MACD | MACD : | -0.7 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 0.9 |
D(3) : | 5.2 |
| RSI | RSI(14): 38.3 |
|||
| 52-week | High : | 20.31 | Low : | 0.72 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ EDSA ] has closed above bottom band by 11.8%. Bollinger Bands are 128.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 25 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 7.81 - 7.89 | 7.89 - 7.93 |
| Low: | 7.04 - 7.14 | 7.14 - 7.19 |
| Close: | 7.11 - 7.26 | 7.26 - 7.36 |
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Fri, 29 May 2026
Edesa Biotech (NASDAQ: EDSA) boosts equity plan and reelects full board - Stock Titan
Tue, 19 May 2026
Edesa Biotech to Present New Data on Paridiprubart in Acute Kidney Injury at European Nephrology Conference - GlobeNewswire
Tue, 19 May 2026
Edesa Biotech, Inc. (EDSA) Presents at Respiratory Innovation Summit 2026 - Slideshow (NASDAQ:EDSA) 2026-05-19 - Seeking Alpha
Thu, 14 May 2026
Edesa Biotech (NASDAQ: EDSA) widens losses and warns of going concern risk - Stock Titan
Thu, 14 May 2026
Drug data show ARDS treatment benefits as vitiligo trial nears - Stock Titan
Thu, 14 May 2026
Edesa Biotech Reports Fiscal 2nd Quarter 2026 Results - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 15 (%) |
| Held by Institutions | 43.6 (%) |
| Shares Short | 514 (K) |
| Shares Short P.Month | 397 (K) |
| EPS | -1.08 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.56 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -55.4 % |
| Return on Equity (ttm) | -96.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.99 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -6.75 |
| PEG Ratio | 0 |
| Price to Book value | 12.89 |
| Price to Sales | 0 |
| Price to Cash Flow | -0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|